SCHEMBL14130986

SCHEMBL14130986

CC(C)CNc1c(N)c2nnnn2c2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.44
MAPT P10636 4/20 0.44
GAA P10253 1/20 0.44
MEN1 O00255 5/20 0.37
KMT2A Q03164 5/20 0.37
TNKS O95271 4/20 0.37
RXFP1 Q9HBX9 3/20 0.37
MAPK1 P28482 2/20 0.37
POLB P06746 2/20 0.37
TP53 P04637 1/20 0.37
ALDH1A1 P00352 5/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HPGD P15428 2/20 0.36
HSD17B10 Q99714 1/20 0.36
NPSR1 Q6W5P4 3/20 0.36
TACR1 P25103 2/20 0.35
RAB9A P51151 2/20 0.34
NPC1 O15118 1/20 0.34
HTT P42858 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7019829 0.84 LATS1 (0.36) KDM4EMAPTGAAMAPK1CYP1A2
SCHEMBL6302291 0.83 KDM4E (0.40) KDM4EMAPTGAAMAPK1
SCHEMBL14143504 0.82 MAPT (0.36) KDM4EMAPTGAAMEN1KMT2A
SCHEMBL1959338 0.80 AS3MT (0.40) MEN1KMT2ATP53ALDH1A1SMN1; SMN2
SCHEMBL6099648 0.80 ALDH1A1 (0.45) MAPTGAAMEN1KMT2ATNKS
SCHEMBL8309976 0.78 POLB (0.41) KDM4EMAPTGAAMEN1KMT2A
SCHEMBL3355418 0.75 LATS1 (0.36) KDM4EMAPTGAAMAPK1CYP1A2
SCHEMBL6106735 0.75 KDM4E (0.43) KDM4EMAPTMEN1KMT2ATNKS
SCHEMBL7107891 0.68 KDM4E (0.36) KDM4EGAARXFP1ALDH1A1SMN1; SMN2
SCHEMBL11326239 0.67 KMT2A (0.53) KDM4EMAPTMEN1KMT2ATNKS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161573-A1 PROCESS FOR THE PREPARATION OF IMIQUIMOD AND INTERMEDIATES THEREOF DIPHARMA S.P.A. (IT) 2008-07-03 US disclosed
US-20080161573-A1 PROCESS FOR THE PREPARATION OF IMIQUIMOD AND INTERMEDIATES THEREOF DIPHARMA S.P.A. (IT) 2008-07-03 US disclosed
US-7301027-B2 Process for the preparation of Imiquimod and intermediates thereof DIPHARMA S.P.A. (IT) 2007-11-27 US disclosed
US-7301027-B2 Process for the preparation of Imiquimod and intermediates thereof DIPHARMA S.P.A. (IT) 2007-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161573-A1 PROCESS FOR THE PREPARATION OF IMIQUIMOD AND INTERMEDIATES THEREOF MYD88, TLR7, MAVS KDM4E 1004/4885MAPT 4284/4885GAA 1731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.